Dopamine D2 receptor density remains constant in treated Parkinson's disease
Identifieur interne : 002975 ( Main/Exploration ); précédent : 002974; suivant : 002976Dopamine D2 receptor density remains constant in treated Parkinson's disease
Auteurs : Mark Guttman [Canada] ; Seeman [Canada] ; Gavin P. Reynolds ; Peter Riederer [Autriche] ; Kurt Jellinger [Autriche] ; Wallace W. Tourtellotte [États-Unis]Source :
- Annals of Neurology [ 0364-5134 ] ; 1986-05.
Abstract
D2 dopamine receptor densities were measured in postmortem samples of the caudate nucleus and putamen from 36 parkinsonian patients. The relationship between the age of the patient, duration of the disease, and duration of L‐dopa therapy versus density of brain D2 dopamine receptors was examined using [3H]spiperone. Receptor density in parkinsonian tissues was constant over the age range of 56 to 90 years, as was the case for control tissues. Density did not change with duration of disease up to 24 years. Treatment with L‐dopa did not cause progressive reduction in receptor density. The diminished clinical response in the final stages of Parkinson's disease is not due to receptor dropout, and must depend on other factors.
Url:
DOI: 10.1002/ana.410190510
Affiliations:
- Autriche, Canada, États-Unis
- Californie, Ontario, Vienne (Autriche)
- Toronto, Vienne (Autriche)
- Université de Toronto
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine D2 receptor density remains constant in treated Parkinson's disease</title><author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name></author><author><name sortKey="Seeman" sort="Seeman" uniqKey="Seeman" last="Seeman">Seeman</name></author><author><name sortKey="Reynolds, Gavin P" sort="Reynolds, Gavin P" uniqKey="Reynolds G" first="Gavin P." last="Reynolds">Gavin P. Reynolds</name></author><author><name sortKey="Riederer, Peter" sort="Riederer, Peter" uniqKey="Riederer P" first="Peter" last="Riederer">Peter Riederer</name></author><author><name sortKey="Jellinger, Kurt" sort="Jellinger, Kurt" uniqKey="Jellinger K" first="Kurt" last="Jellinger">Kurt Jellinger</name></author><author><name sortKey="Tourtellotte, Wallace W" sort="Tourtellotte, Wallace W" uniqKey="Tourtellotte W" first="Wallace W." last="Tourtellotte">Wallace W. Tourtellotte</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D401455914CA1C7B42C3C05CA253D6D47BA6F19A</idno><date when="1986" year="1986">1986</date><idno type="doi">10.1002/ana.410190510</idno><idno type="url">https://api.istex.fr/document/D401455914CA1C7B42C3C05CA253D6D47BA6F19A/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001811</idno><idno type="wicri:Area/Main/Curation">001568</idno><idno type="wicri:Area/Main/Exploration">002975</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dopamine D2 receptor density remains constant in treated Parkinson's disease</title><author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine and Faculty of Medicine, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Seeman" sort="Seeman" uniqKey="Seeman" last="Seeman">Seeman</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology, Faculty of Medicine, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Reynolds, Gavin P" sort="Reynolds, Gavin P" uniqKey="Reynolds G" first="Gavin P." last="Reynolds">Gavin P. Reynolds</name><affiliation><wicri:noCountry code="subField">England CB2 2QQ</wicri:noCountry></affiliation></author><author><name sortKey="Riederer, Peter" sort="Riederer, Peter" uniqKey="Riederer P" first="Peter" last="Riederer">Peter Riederer</name><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>Ludwig Boltzmann Institute for Clinical Neurobiology, Lainz Hospital, 1130 Vienna</wicri:regionArea><placeName><region type="land" nuts="2">Vienne (Autriche)</region><settlement type="city">Vienne (Autriche)</settlement></placeName></affiliation></author><author><name sortKey="Jellinger, Kurt" sort="Jellinger, Kurt" uniqKey="Jellinger K" first="Kurt" last="Jellinger">Kurt Jellinger</name><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>Ludwig Boltzmann Institute for Clinical Neurobiology, Lainz Hospital, 1130 Vienna</wicri:regionArea><placeName><region type="land" nuts="2">Vienne (Autriche)</region><settlement type="city">Vienne (Autriche)</settlement></placeName></affiliation></author><author><name sortKey="Tourtellotte, Wallace W" sort="Tourtellotte, Wallace W" uniqKey="Tourtellotte W" first="Wallace W." last="Tourtellotte">Wallace W. Tourtellotte</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>National Neurological Research Bank, VA Wadsworth Medical Center, Neurology Research, Los Angeles</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1986-05">1986-05</date><biblScope unit="volume">19</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="487">487</biblScope><biblScope unit="page" to="492">492</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">D401455914CA1C7B42C3C05CA253D6D47BA6F19A</idno><idno type="DOI">10.1002/ana.410190510</idno><idno type="ArticleID">ANA410190510</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">D2 dopamine receptor densities were measured in postmortem samples of the caudate nucleus and putamen from 36 parkinsonian patients. The relationship between the age of the patient, duration of the disease, and duration of L‐dopa therapy versus density of brain D2 dopamine receptors was examined using [3H]spiperone. Receptor density in parkinsonian tissues was constant over the age range of 56 to 90 years, as was the case for control tissues. Density did not change with duration of disease up to 24 years. Treatment with L‐dopa did not cause progressive reduction in receptor density. The diminished clinical response in the final stages of Parkinson's disease is not due to receptor dropout, and must depend on other factors.</div></front></TEI><affiliations><list><country><li>Autriche</li><li>Canada</li><li>États-Unis</li></country><region><li>Californie</li><li>Ontario</li><li>Vienne (Autriche)</li></region><settlement><li>Toronto</li><li>Vienne (Autriche)</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><noCountry><name sortKey="Reynolds, Gavin P" sort="Reynolds, Gavin P" uniqKey="Reynolds G" first="Gavin P." last="Reynolds">Gavin P. Reynolds</name></noCountry><country name="Canada"><region name="Ontario"><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name></region><name sortKey="Seeman" sort="Seeman" uniqKey="Seeman" last="Seeman">Seeman</name></country><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Riederer, Peter" sort="Riederer, Peter" uniqKey="Riederer P" first="Peter" last="Riederer">Peter Riederer</name></region><name sortKey="Jellinger, Kurt" sort="Jellinger, Kurt" uniqKey="Jellinger K" first="Kurt" last="Jellinger">Kurt Jellinger</name></country><country name="États-Unis"><region name="Californie"><name sortKey="Tourtellotte, Wallace W" sort="Tourtellotte, Wallace W" uniqKey="Tourtellotte W" first="Wallace W." last="Tourtellotte">Wallace W. Tourtellotte</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002975 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002975 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D401455914CA1C7B42C3C05CA253D6D47BA6F19A
|texte= Dopamine D2 receptor density remains constant in treated Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |